These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 37174032)
1. The Application of an Extracellular Vesicle-Based Biosensor in Early Diagnosis and Prediction of Chemoresponsiveness in Ovarian Cancer. Asare-Werehene M; Hunter RA; Gerber E; Reunov A; Brine I; Chang CY; Chang CC; Shieh DB; Burger D; Anis H; Tsang BK Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37174032 [TBL] [Abstract][Full Text] [Related]
2. Predicting chemoresponsiveness in epithelial ovarian cancer patients using circulating small extracellular vesicle-derived plasma gelsolin. Gerber E; Asare-Werehene M; Reunov A; Burger D; Le T; Carmona E; Mes-Masson AM; Tsang BK J Ovarian Res; 2023 Jan; 16(1):14. PubMed ID: 36642715 [TBL] [Abstract][Full Text] [Related]
3. Plasma Gelsolin Confers Chemoresistance in Ovarian Cancer by Resetting the Relative Abundance and Function of Macrophage Subtypes. Asare-Werehene M; Tsuyoshi H; Zhang H; Salehi R; Chang CY; Carmona E; Librach CL; Mes-Masson AM; Chang CC; Burger D; Yoshida Y; Tsang BK Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205790 [TBL] [Abstract][Full Text] [Related]
4. The regulation of plasma gelsolin by DNA methylation in ovarian cancer chemo-resistance. Manzoor HB; Asare-Werehene M; Pereira SD; Satyamoorthy K; Tsang BK J Ovarian Res; 2024 Jan; 17(1):15. PubMed ID: 38216951 [TBL] [Abstract][Full Text] [Related]
5. Exosomal Plasma Gelsolin Is an Immunosuppressive Mediator in the Ovarian Tumor Microenvironment and a Determinant of Chemoresistance. Onuma T; Asare-Werehene M; Yoshida Y; Tsang BK Cells; 2022 Oct; 11(20):. PubMed ID: 36291171 [TBL] [Abstract][Full Text] [Related]
6. Plasma Gelsolin Inhibits CD8 Asare-Werehene M; Communal L; Carmona E; Han Y; Song YS; Burger D; Mes-Masson AM; Tsang BK Cancer Res; 2020 Sep; 80(18):3959-3971. PubMed ID: 32641415 [TBL] [Abstract][Full Text] [Related]
7. Pre-operative Circulating Plasma Gelsolin Predicts Residual Disease and Detects Early Stage Ovarian Cancer. Asare-Werehene M; Communal L; Carmona E; Le T; Provencher D; Mes-Masson AM; Tsang BK Sci Rep; 2019 Sep; 9(1):13924. PubMed ID: 31558772 [TBL] [Abstract][Full Text] [Related]
8. The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance. Asare-Werehene M; Nakka K; Reunov A; Chiu CT; Lee WT; Abedini MR; Wang PW; Shieh DB; Dilworth FJ; Carmona E; Le T; Mes-Masson AM; Burger D; Tsang BK Oncogene; 2020 Feb; 39(7):1600-1616. PubMed ID: 31700155 [TBL] [Abstract][Full Text] [Related]
9. Plasma Gelsolin Inhibits Natural Killer Cell Function and Confers Chemoresistance in Epithelial Ovarian Cancer. Onuma T; Asare-Werehene M; Fujita Y; Yoshida Y; Tsang BK Cells; 2024 May; 13(11):. PubMed ID: 38891037 [TBL] [Abstract][Full Text] [Related]
10. Chemo-small extracellular vesicles released in cisplatin-resistance ovarian cancer cells are regulated by the lysosomal function. Cerda-Troncoso C; Grünenwald F; Arias-Muñoz E; Cavieres VA; Caceres-Verschae A; Hernández S; Gaete-Ramírez B; Álvarez-Astudillo F; Acuña RA; Ostrowski M; Burgos PV; Varas-Godoy M J Extracell Biol; 2024 Jun; 3(6):e157. PubMed ID: 38947172 [TBL] [Abstract][Full Text] [Related]
11. Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability. Ali AY; Kim JY; Pelletier JF; Vanderhyden BC; Bachvarov DR; Tsang BK Mol Carcinog; 2015 Nov; 54(11):1301-14. PubMed ID: 25154814 [TBL] [Abstract][Full Text] [Related]
12. Sensitive phenotyping of serum extracellular vesicles on a SERS-microfluidic platform for early-stage clinical diagnosis of ovarian carcinoma. Chen X; Tang J; Zhao Y; Wang R; Sang S; Yu F; Xing Y Biosens Bioelectron; 2025 Jan; 267():116724. PubMed ID: 39260102 [TBL] [Abstract][Full Text] [Related]
13. Characterization of ovarian cancer-derived extracellular vesicles by surface-enhanced Raman spectroscopy. Ćulum NM; Cooper TT; Lajoie GA; Dayarathna T; Pasternak SH; Liu J; Fu Y; Postovit LM; Lagugné-Labarthet F Analyst; 2021 Nov; 146(23):7194-7206. PubMed ID: 34714898 [TBL] [Abstract][Full Text] [Related]
14. Exploration of Potential Diagnostic Value of Protein Content in Serum Small Extracellular Vesicles for Early-Stage Epithelial Ovarian Carcinoma. Li P; Bai Y; Shan B; Zhang W; Liu Z; Zhu Y; Xu X; Chen Q; Sheng X; Deng X; Guo Z; Zhang D; Wang H; Zhang Y; Hu Y Front Oncol; 2021; 11():707658. PubMed ID: 34604046 [TBL] [Abstract][Full Text] [Related]
15. Involvement of small extracellular vesicle-derived TIE-1 in the chemoresistance of ovarian cancer cells. Misawa T; Toyoshima M; Kitatani K; Ishibashi M; Hasegawa-Minato J; Shigeta S; Yaegashi N Cancer Treat Res Commun; 2021; 27():100364. PubMed ID: 33812182 [TBL] [Abstract][Full Text] [Related]
16. YM155 sensitizes ovarian cancer cells to cisplatin inducing apoptosis and tumor regression. Mir R; Stanzani E; Martinez-Soler F; Villanueva A; Vidal A; Condom E; Ponce J; Gil J; Tortosa A; Giménez-Bonafé P Gynecol Oncol; 2014 Jan; 132(1):211-20. PubMed ID: 24262875 [TBL] [Abstract][Full Text] [Related]
17. P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism. Al-Bahlani S; Fraser M; Wong AY; Sayan BS; Bergeron R; Melino G; Tsang BK Oncogene; 2011 Oct; 30(41):4219-30. PubMed ID: 21516125 [TBL] [Abstract][Full Text] [Related]
18. Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells. Dasari VR; Carey DJ; Gogoi R BMC Cancer; 2020 Apr; 20(1):273. PubMed ID: 32245422 [TBL] [Abstract][Full Text] [Related]
19. p53 Promotes chemoresponsiveness by regulating hexokinase II gene transcription and metabolic reprogramming in epithelial ovarian cancer. Han CY; Patten DA; Lee SG; Parks RJ; Chan DW; Harper ME; Tsang BK Mol Carcinog; 2019 Nov; 58(11):2161-2174. PubMed ID: 31486135 [TBL] [Abstract][Full Text] [Related]